<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2016.3694</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-3694</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The influence of exendin-4 intervention on -obese diabetic mouse blood and the pancreatic tissue immune microenvironment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>He</surname><given-names>Jinshui</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Lian</surname><given-names>Chaowei</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Fang</surname><given-names>Yanling</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jinzhi</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Huowang</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Ye</surname><given-names>Xiaoling</given-names></name>
<xref rid="af1-etm-0-0-3694" ref-type="aff"/>
<xref rid="c1-etm-0-0-3694" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-3694">Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-3694"><italic>Correspondence to</italic>: Dr Xiaoling Ye, Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University, 55 Shengli West Road, Zhangzhou, Fujian 363000, P.R. China, E-mail: <email>ye_xiaoling1@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>12</day>
<month>09</month>
<year>2016</year></pub-date>
<volume>12</volume>
<issue>5</issue>
<fpage>2893</fpage>
<lpage>2898</lpage>
<history>
<date date-type="received"><day>17</day><month>05</month><year>2016</year></date>
<date date-type="accepted"><day>06</day><month>09</month><year>2016</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; He et al.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The aim of the study was to determine the influence of exendin-4 intervention on non-obese diabetic (NOD) mouse blood and the pancreatic tissue immune microenvironment. A total of 40 clean NOD mice were used in the study and randomly divided into 4 groups (n=10/group). The first group was blank control group D with normal saline intervention, and with different doses of exendin, i.e.,-4 2, 4 and 8 &#x00B5;g/kg/day. The three remaining groups were: i) Low-dose group A; ii) medium-dose group B; and iii) high-dose group C. Mice in the four groups went through intervention for 8 weeks. Their mass and blood glucose levels were tested each week. After 8 weeks, the mice were sacrificed, and mouse serum samples were reserved. The ELISA method was used to test peripheral blood (PB), IL-2, IFN-&#x03B3; and IL-10 levels. Pancreatic samples were created. Immunohistochemistry was used to observe the infiltration degree of mouse pancreatitis and the local expression state of pancreatic IL-10. Mouse pancreatic tissues were suspended in pancreatic cell suspension. Flow cytometry was used to test the state of T-cell subsets CD4 and CD25. Mouse pancreatitis in control group D was mainly at grade 2and 3. Under a light microscope, it was observed that pancreatic cell morphology was in disorder, and the size and quantity of the pancreas was small. Mouse pancreatitis in the exendin-4 low-dose group A, medium-dose group B and high-dose group C was mainly at grade 0 and 1. Under a light microscope, it was observed that pancreatic cell morphology improved, the infiltration degree of lymphocyte was improved and pancreatic islet size was restored somewhat. Additionally, a few brownish granules were identified within the pancreatic sample cells in control group D. There were many brownish granules with deep color within the pancreatic sample cells in exendin-4 low-dose group A, medium-dose group B and high-dose group C. IL-10 immunohistochemistry scores in the low-dose group A, medium-dose group B and high-dose group C were 3.82&#x00B1;0.72, 4.34&#x00B1;0.86 and 4.81&#x00B1;0.94, respectively, and were higher than the score of 2.25&#x00B1;0.63 in control group D. CD4&#x002B;CD25&#x002B;T-cell proportions in mouse pancreatic tissues of low-dose group A, medium-dose group B and high-dose group C were 5.31, 5.53 and 5.74&#x0025;, respectively, which were higher than that of the CD4&#x002B;CD25&#x002B;T-cell proportion (1.62&#x0025; in control group D). The CD4&#x002B;CD25<sup>high</sup> T-cell proportion in CD4&#x002B;T-cells in group A, B and C increased. Compared with control group D, serum IL-10 levels in the exendin-4 low-dose group A, medium-dose group B and high-dose group C increased (P&#x003C;0.05), while levels of IL-2 and IFN-&#x03B3; decreased (P&#x003C;0.05). Additionally, the difference of serum IL-10, IL-2 and IFN-&#x03B3; levels in the low-dose group A, medium-dose group B and high-dose group C was of statistical significance (P&#x003C;0.05). Exendin-4 intervention can increase quantities of CD4 and CD8&#x002B;T cells in NOD mouse pancreases, with PB IL-10 expression and local expression of IL-10 in pancreatic tissues. It also can inhibit the expression of serum IL-2 and IFN-&#x03B3;, regulate the organism immune microenvironment and prevent diabetes. CD4&#x002B;CD25<sup>high</sup> T cells increase in NOD tumor infiltration lymphocytes mediated by exendin-4 intervention, which may be related to the fact that exendin-4 inhibits the lethal effect of CD8&#x002B;T cells through contact among cells and eventually exerts immunosuppressive effect.</p>
</abstract>
<kwd-group>
<kwd>exendin-4</kwd>
<kwd>NOD mice</kwd>
<kwd>diabetes</kwd>
<kwd>immune microenvironment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Type 1 diabetes is an autoimmune disease, and the prominent population affected by the disease is teenagers. In recent years, the number of individuals diagnosed with the disease has increased. Once affected by the disease, the patient undergoes lifelong insulin treatment, which can pose an economic burden to the patient and family. Patients with type 1 diabetes suffer from multiple complications, which can lead to disabling and lethal factors (<xref rid="b1-etm-0-0-3694" ref-type="bibr">1</xref>).</p>
<p>To the best of our knowledge, few studies are available on the exact pathogenesis of type 1 diabetes, the variation of patient blood and the pancreatic tissue immune microenvironment (<xref rid="b2-etm-0-0-3694" ref-type="bibr">2</xref>&#x2013;<xref rid="b4-etm-0-0-3694" ref-type="bibr">4</xref>). Non-obese diabetic (NOD) mice can spontaneously generate autoimmune disease, and their pathogenic process is similar to that of type 1 diabetes of human beings. Consequently, a NOD rodent animal model should be established to probe into morbidity and develop a treatment intervention mechanism for human type 1 diabetes (<xref rid="b5-etm-0-0-3694" ref-type="bibr">5</xref>). Exendin-4 is a type of polypeptide hormone separated from Gila monster saliva. This hormone is a broad application prospect in treating type 2 diabetes (<xref rid="b6-etm-0-0-3694" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-3694" ref-type="bibr">7</xref>). However, there is little research or studies on exendin-4 as an intervention mechanism in type 1 diabetes treatment. In order to determine the influence of exendin-4 intervention on NOD mouse blood and the pancreatic tissue immune microenvironment, a NOD mouse model was established for the experiments. A variation in T-cell subset CD8, CD4 and CD25 in NOD mouse peripheral blood and pancreatic tissue, as well as in the contents of cell factors IL-2, IFN-&#x03B3; and IL-10 after low-dose, medium-dose and high-dose exendin-4 intervention was observed.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Materials</title>
<p>A total of 40 NOD/Lt mice were purchased from the Institute of Experimental Animals of the Chinese Academy of Medical Sciences. There were 20 male and 20 female mice, with a weight of 17&#x2013;25 g. Exendin-4 reagent (Kangtai Biotechnology, Beijing, China); hematoxylin and eosin (H&#x0026;E) dye liquor (Beijing Solarbio Science and Technology, Co., Ltd., Beijing, China); IL-2, IL-10 and IFN-&#x03B3; reagent kits (Shanghai Biotechnology, Shanghai, China); monoclonal CD4 rabbit antibody (Abcam, Cambridge, MA, USA; catalog no.: ab133616; dilution, 1:100) and monoclonal CD8 rabbit antibody (Abcam; catalog no.: ab22378; dilution, 1:100); a flow cytometer (Beijing Kexue Yingye Science and Technology Development, Beijing, China); microplate reader (Jinan Guangyao Medical Equipment, Jinan, China); centrifugal machine (Shanghai Puyuan Instrument, Shanghai, China); and an optical microscope (Shenzhen Final Technology, Shenzhen, China) were used in the study.</p>
<p>The present study was approved by the ethics committee of Fujian Medical University (Fujian, China).</p>
</sec>
<sec>
<title>Methods</title>
<p>A random number table was used to divide 40 clean and healthy NOD mice into 4 groups (n=10/group) as follows: One blank control group D with normal saline intervention, and the remaining three groups with exendin-4 intervention. According to the different exendin-4 doses of 2, 4 and 8 &#x00B5;g/kg/day, they were called the low-dose group A, medium-dose group B and high-dose group C, respectively. The four groups of mice were intervened for 8 weeks, after which they were sacrificed by cervical dislocation. An inner canthus method was used to take ~1 ml of whole blood, which was then centrifuged at 5,000 &#x00D7; g for 10 min at 4&#x00B0;C. Serum was kept at &#x2212;20&#x00B0;C to test serum IL-2, IL-10 and IFN-&#x03B3;. Pancreatic tissues were selected to conduct T-cell subset determination, while other subsets continued to be observed.</p>
</sec>
<sec>
<title>Observation of pancreatitis infiltration degree</title>
<p>Pancreatic samples were embedded with paraffin, and then turned into tissue sections with H&#x0026;E dyeing to be observed under a light microscope (Olympus, Tokyo, Japan). Pathology personnel used a double-blind method to determine the infiltration degree of pancreatitis. The grade of pancreatitis infiltration degree was divided as follows: i) Grade 0: Pancreas islet was complete without lymphocyte infiltration; ii) grade 1: lymphocytes infiltrated around the pancreas islet or &#x003C;25&#x0025; pancreas islet area was affected; iii) grade 2: 25&#x2013;50&#x0025; pancreas islet area was affected; and iv) grade 3: &#x003E;50&#x0025; pancreas islet area was affected. According to the above grading standard, the pancreatic sections of the four groups were observed under a &#x00D7;5-x400 microscope.</p>
</sec>
<sec>
<title>Assessment of local expression of pancreatic IL-10</title>
<p>Immunohistochemistry was used to observe the expression of the <italic>IL-10</italic> gene in local pancreatic samples. Brownish granules in cytoplasm were considered positive cells. Positive cell percentage and dyeing intensity were calculated. The positive cell percentage was calculated as: i) &#x003C;1&#x0025; was 0; ii) 1&#x2013;10&#x0025; was 1; iii) 11&#x2013;50&#x0025; was 2; iv) 51&#x2013;80&#x0025; was 3; and v) &#x003E;80&#x0025; was 4. The dyeing intensity of granules was calculated as: i) No dyeing was 0; ii) faint yellow was 1; iii) yellow was 2; and iv) brown was 3. The product of positive cell percentage and dyeing intensity determined the immunohistochemistry score as follows: 0 score (&#x2212;); 1&#x2013;4 scores (&#x002B;); 5&#x2013;8 scores (&#x002B;&#x002B;); and 9&#x2013;12 scores (&#x002B;&#x002B;&#x002B;).</p>
</sec>
<sec>
<title>Determination of pancreatic tissue T-cell subset</title>
<p>After the mice were sacrificed, they were sterilized with alcohol. Pancreatic tissues were separated through an aseptic technique. Nearby connective tissues and pancreatic tissues were removed and rinsed twice in Hanks&#x0027; liquid. Ophthalmic scissors were used to cut the tissues into pasty sections. A tip sucker was used to blow and disperse pancreatic cells, while a 300-mesh net was used to implement infiltration. A lymphocyte-separating medium was used to extract lymphocytes at rotating speeds of 400 &#x00D7; g. They were then centrifuged for 20 min. The suspended layer of lymphocytes was extracted after a 2 ml pH 7.4 phosphate buffer saline (PBS) working solution was added. The lymphocytes were centrifuged for 5 min at 800 &#x00D7; g. The supernatant was discarded, and the cell concentration was adjusted to 2&#x00D7;10<sup>9</sup> cells/l. Under a microscope, 0.4&#x0025; trypan blue was used to count living cells. The cell survival rate was determined to be &#x003E;95&#x0025;. A 100 &#x00B5;l pancreatic single-cell suspension at a concentration of 2&#x00D7;10<sup>9</sup>/ml was measured at 25&#x00B0;C and kept in the dark. The suspension was then incubated with 10 &#x00B5;l CD8-FITC and 10 &#x00B5;l CD4-PE fluorescent antibody for 15 min. A 2-m erythrocyte lysate buffer was added to the suspension to incubate it for 10 min. A 2-ml PBS solution was then added to conduct centrifugation at 800 &#x00D7; g for 5 min. PBS washing was then repeated twice (the method used before), the supernatant was removed, and 200 &#x00B5;l PBS solution was added to each tube to conduct FCM detection. Macintosh (Apple, Inc., Cupertino, CA, USA) was the data processing system used. Cells were analyzed using CellQuest software (BD Biosciences, San Jose, CA, USA). Grating was conducted on lymphocytes on forward and lateral angular scattering diagrams. A logarithmic method was used to acquire fluorescence signals before 1&#x00D7;10<sup>4</sup> cells were taken and analyzed under the same software. Serum of IL-2, IL-10 and IFN-&#x03B3; were determined using ELISA. Operating steps were performed with ELISA reagent kits of IL-2, IL-10 and IFN-&#x03B3;. The samples were determined in the same batch.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>SPSS 21.0 statistical software (IBM SPSS, Armonk, NY, USA) was used to conduct statistical analysis. Experimental data were presented as mean &#x00B1; standard deviation, t-test or t&#x0027;-test. A &#x03C7;<sup>2</sup> test was conducted on experimental results. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Pancreatitis infiltration degree</title>
<p>Pancreatitis of mice in control group D was mainly at grade 2 and 3. Under a light microscope, it was observed that pancreatic cell morphology was in disorder, and the size and quantity of the pancreas was small. Mouse pancreatitis in exendin-4 low-dose group A, medium-dose group B and high-dose group C was mainly at grade 0 and 1. Under the light microscope, it was observed that pancreatic cell morphology improved, infiltration degree of lymphocyte improved and pancreatic islet size was restored somewhat.</p>
</sec>
<sec>
<title>Local expression of IL-10 in pancreatic tissues</title>
<p>Under the light microscope, numerous brown granules with deep color within pancreatic sample cells in exendin-4 low-dose group A, medium-dose group B and high-dose group C (<xref rid="f1-etm-0-0-3694" ref-type="fig">Figs. 1</xref>&#x2013;<xref rid="f3-etm-0-0-3694" ref-type="fig">3</xref>) were observed. There were a few brown granules within pancreatic sample cells in control group D (<xref rid="f4-etm-0-0-3694" ref-type="fig">Fig. 4</xref>). IL-10 immunohistochemistry scores in low-dose group A, medium-dose group B and high-dose group C were 3.82&#x00B1;0.72, 4.34&#x00B1;0.86 and 4.81&#x00B1;0.94, respectively, all of which were higher than the immunohistochemistry score of 2.25&#x00B1;0.63 in group D.</p>
</sec>
<sec>
<title>Test results of FCM</title>
<p>The CD4&#x002B;CD25&#x002B;T-cell proportions in pancreatic tissues in exendin-4 low-dose group A, medium-dose group B and high-dose group C were 5.31, 5.53 and 5.74&#x0025;, respectively, all of which were higher than the CD4&#x002B;CD25&#x002B;T-cell proportions of 1.62&#x0025; in group D, as shown in <xref rid="f5-etm-0-0-3694" ref-type="fig">Figs. 5</xref>&#x2013;<xref rid="f8-etm-0-0-3694" ref-type="fig">8</xref> (right upper quadrant of each figure was a CD4&#x002B;CD25&#x002B;T cell subset). The proportions of CD4&#x002B;CD25<sup>high</sup> T-cells in CD4&#x002B;T cells increased in groups A, B and C.</p>
</sec>
<sec>
<title>Comparison of serum IL-2, IL-10 and IFN-&#x03B3;</title>
<p>Compared with control group D, serum IL-10 levels in exendin-4 low-dose group A, medium-dose group B and high-dose group C increased (P&#x003C;0.05), while IL-2 and IFN-&#x03B3; levels decreased (P&#x003C;0.05). The difference of serum IL-10, IL-2 and IFN-&#x03B3; levels existing in IFN-&#x03B3; was of statistical significance (P&#x003C;0.05) (<xref rid="tI-etm-0-0-3694" ref-type="table">Table I</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Previous findings have shown that the occurrence of type 1 diabetes involves phases such as cellular imbalance, inflammatory cell recruitment and inflammatory cell effect (<xref rid="b8-etm-0-0-3694" ref-type="bibr">8</xref>). The classical immunoregulation imbalance theory states that, the imbalance of Th1/Th2 cell subset and disorder of body immunologic functions are key factors inducing type 1 diabetes (<xref rid="b9-etm-0-0-3694" ref-type="bibr">9</xref>,<xref rid="b10-etm-0-0-3694" ref-type="bibr">10</xref>). IL-2, IFN-&#x03B3; and others are common Th1 cell factors that can upregulate pro-inflammatory factors, thus generating damage on pancreatic &#x03B2; cells. IL-10, IL-4 and others belong to Th2 cell factors, which can downregulate the activity of Th1 cells and have a preventative effect on type 1 diabetes (<xref rid="b11-etm-0-0-3694" ref-type="bibr">11</xref>). The present study has shown that compared with control group D, serum IL-10 levels in exendin-4 low-dose group A, medium-dose group B and high-dose group C increased (P&#x003C;0.05), while IL-2 and IFN-&#x03B3; levels decreased (P&#x003C;0.05). The difference of the serum IL-10, IL-2 and IFN-&#x03B3; levels existing among IFN-&#x03B3; were of statistical significance (P&#x003C;0.05). Thus, it can be seen that exendin-4 intervention can reduce the expression of NOD mouse serum IL- 2 and IFN-&#x03B3;, elevate the expression of serum IL-10 and exert a protective effect on pancreatic &#x03B2; cells.</p>
<p>T lymphocytes are closely related to diabetes pancreatitis. The inflammatory reaction induced by cell factors that are released by body CD4&#x002B;T lymphocytes and cell toxic reaction mediated by body CD8&#x002B;T lymphocytes are considered the main forms of cellular immunity induced by T lymphocytes (<xref rid="b12-etm-0-0-3694" ref-type="bibr">12</xref>&#x2013;<xref rid="b14-etm-0-0-3694" ref-type="bibr">14</xref>). If CD4&#x002B;T lymphocyte subsets gradually increase, then multiple types of cell factors can be released. While these cell factors, may enhance the inflammatory reaction of lymphocyte infiltration, form lethal effects on antigens and generate adverse effects, they also can facilitate cellular immunity and humoral immunity to a certain degree, and then promote effective removal of virus <italic>in vivo</italic>. Regulatory T-cells (CD4&#x002B;CD25<sup>high</sup> Foxp3&#x002B;T reg) are a type of T-cell subset with immunomodulating functions that has been verified in recent years. It can maintain self-stabilization of an immune system while regulating the immune response (<xref rid="b15-etm-0-0-3694" ref-type="bibr">15</xref>&#x2013;<xref rid="b17-etm-0-0-3694" ref-type="bibr">17</xref>). The present study has shown that CD4&#x002B;CD25&#x002B;T-cell proportions in pancreatic tissues of exendin-4 low-dose group A, medium-dose group B and high-dose group C were 5.31, 5.53 and 5.74&#x0025;, respectively, all of which were higher than the CD4&#x002B;CD25&#x002B;T-cell proportion of 1.62&#x0025; in control group D. CD4&#x002B;CD25<sup>high</sup> T-cells in groups A, B and C occupied an increasing proportion in CD4&#x002B;T-cells. Studies have indicated that CD4&#x002B;CD25<sup>high</sup> T increased in NOD tumor infiltration lymphocytes under exendin-4 intervention, which may be associated with the fact that it exerted an immunosupressive effect by inhibiting the lethal effects of CD8&#x002B;T cells through contact among cells (<xref rid="b18-etm-0-0-3694" ref-type="bibr">18</xref>).</p>
<p>Previous studies reported that, IL-10 can reduce the accumulated morbidity of diabetes, lower the inflammation degree of pancreas islets and relieve or prevent the occurrence and development of type 1 diabetes (<xref rid="b19-etm-0-0-3694" ref-type="bibr">19</xref>,<xref rid="b20-etm-0-0-3694" ref-type="bibr">20</xref>). Notably diabetes is rarely diagnosed in an early phase. The lymphocyte infiltration degree may be serious once the patient is diagnosed with diabetes, and there are quite a few residual pancreatic &#x03B2; cells (<xref rid="b21-etm-0-0-3694" ref-type="bibr">21</xref>). The present findings have shown that pancreatitis of mice in control group D was mainly at grade 2 and 3, and under a light microscope, it was observed that pancreatic cell morphology was in disorder and the size and quantity of the pancreas was small. Pancreatitis in exendin-4 low-dose group A, medium-dose group B and high-dose group C was mainly at grade 0 and 1, and light microscopy showed that pancreatic cell morphology and lymphocyte infiltration improved, and the size of the pancreas was recovered. Additionally, a few brown granules with deep color were found within the pancreatic sample cells in control group D. IL-10 immunohistochemistry scores in low-dose group A, medium-dose group B and high-dose group C were (3.82&#x00B1;0.72), (4.34&#x00B1;0.86) and (4.81&#x00B1;0.94), respectively, all of which were higher than that in control group D (2.25&#x00B1;0.63). We conjectured that exendin-4 intervention elevates IL-10 levels in pancreatic tissues, downregulates bioactivity of Th1 cell factors through overexpression of IL-10, is regulated in the <italic>in vivo</italic> immune microenvironment and prevents the occurrence and development of diabetes.</p>
<p>In summary, NOD mouse body immune function is low, while the regulatory mechanism of its body immunity is in a state of disorder. Pancreatic tissue necrosis and inflammatory infiltration are serious. Exendin-4 intervention can exert certain regulatory effects on the IL-2, IFN-&#x03B3;, IL-10 and T lymphocyte subset of NOD mice. By reducing the expression of serum IL- 2 and IFN-&#x03B3;, it elevates IL-10 expression in serum and pancreatic tissues and increases the quantity of CD8&#x002B;, CD4&#x002B; and CD25&#x002B; T cells in pancreatic tissues, thus eliminating inflammatory factors, boosting pancreatic tissue recovery and improving lymphocyte infiltration degree. Thus, the results of the current study, revealed the mechanism involved in exendin-4 on NOD mouse blood and the pancreatic tissue immune microenvironment.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was funded by the Natural Science Foundation of Fujian province (grant no. 2016J01650).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-3694"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>K</given-names></name><name><surname>H&#x00FC;hn</surname><given-names>MH</given-names></name><name><surname>Flodstr&#x00F6;m-Tullberg</surname><given-names>M</given-names></name></person-group><article-title>Immunology in the clinic review series; focus on type 1 diabetes and viruses: The innate immune response to enteroviruses and its possible role in regulating type 1 diabetes</article-title><source>Clin Exp Immunol</source><volume>168</volume><fpage>30</fpage><lpage>38</lpage><year>2012</year><pub-id pub-id-type="doi">10.1111/j.1365-2249.2011.04557.x</pub-id><pub-id pub-id-type="pmid">22385234</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-3694"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinale</surname><given-names>FG</given-names></name><name><surname>Stolen</surname><given-names>CM</given-names></name></person-group><article-title>Biomarkers and heart disease: What is translational success?</article-title><source>J Cardiovasc Transl Res</source><volume>6</volume><fpage>447</fpage><lpage>448</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s12265-013-9477-9</pub-id><pub-id pub-id-type="pmid">23733544</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-3694"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diana</surname><given-names>J</given-names></name><name><surname>Lehuen</surname><given-names>A</given-names></name></person-group><article-title>Macrophages and &#x03B2;-cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes</article-title><source>EMBO Mol Med</source><volume>6</volume><fpage>1090</fpage><lpage>1104</lpage><year>2014</year><pub-id pub-id-type="doi">10.15252/emmm.201404144</pub-id><pub-id pub-id-type="pmid">24968718</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-3694"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>O</given-names></name><name><surname>Ntalianis</surname><given-names>A</given-names></name><name><surname>Winjs</surname><given-names>W</given-names></name><name><surname>Delrue</surname><given-names>L</given-names></name><name><surname>Dierickx</surname><given-names>K</given-names></name><name><surname>Auer</surname><given-names>R</given-names></name><name><surname>Rodondi</surname><given-names>N</given-names></name><name><surname>Mangiacapra</surname><given-names>F</given-names></name><name><surname>Trana</surname><given-names>C</given-names></name><name><surname>Hamilos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease</article-title><source>J Cardiovasc Transl Res</source><volume>6</volume><fpage>536</fpage><lpage>544</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s12265-013-9468-x</pub-id><pub-id pub-id-type="pmid">23670230</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-3694"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyler</surname><given-names>JS</given-names></name></person-group><article-title>Prevention and reversal of type 1 diabetes - past challenges and future opportunities</article-title><source>Diabetes Care</source><volume>38</volume><fpage>997</fpage><lpage>1007</lpage><year>2015</year><pub-id pub-id-type="doi">10.2337/dc15-0349</pub-id><pub-id pub-id-type="pmid">25998292</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-3694"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminitz</surname><given-names>A</given-names></name><name><surname>Mizrahi</surname><given-names>K</given-names></name><name><surname>Ash</surname><given-names>S</given-names></name><name><surname>Ben-Nun</surname><given-names>A</given-names></name><name><surname>Askenasy</surname><given-names>N</given-names></name></person-group><article-title>Stable activity of diabetogenic cells with age in NOD mice: Dynamics of reconstitution and adoptive diabetes transfer in immunocompromised mice</article-title><source>Immunology</source><volume>142</volume><fpage>465</fpage><lpage>473</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/imm.12277</pub-id><pub-id pub-id-type="pmid">24601987</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-3694"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savinov</surname><given-names>AY</given-names></name><name><surname>Strongin</surname><given-names>AY</given-names></name></person-group><article-title>Targeting the T-cell membrane type-1 matrix metalloproteinase-CD44 axis in a transferred type 1 diabetes model in NOD mice</article-title><source>Exp Ther Med</source><volume>5</volume><fpage>438</fpage><lpage>442</lpage><year>2013</year><pub-id pub-id-type="pmid">23403478</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-3694"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YG</given-names></name><name><surname>Forsberg</surname><given-names>MH</given-names></name><name><surname>Khaja</surname><given-names>S</given-names></name><name><surname>Ciecko</surname><given-names>AE</given-names></name><name><surname>Hessner</surname><given-names>MJ</given-names></name><name><surname>Geurts</surname><given-names>AM</given-names></name></person-group><article-title>Gene targeting in NOD mouse embryos using zinc-finger nucleases</article-title><source>Diabetes</source><volume>63</volume><fpage>68</fpage><lpage>74</lpage><year>2014</year><pub-id pub-id-type="doi">10.2337/db13-0192</pub-id><pub-id pub-id-type="pmid">23974926</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-3694"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachmiel</surname><given-names>M</given-names></name><name><surname>Bloch</surname><given-names>O</given-names></name><name><surname>Bistritzer</surname><given-names>T</given-names></name><name><surname>Weintrob</surname><given-names>N</given-names></name><name><surname>Ofan</surname><given-names>R</given-names></name><name><surname>Koren-Morag</surname><given-names>N</given-names></name><name><surname>Rapoport</surname><given-names>MJ</given-names></name></person-group><article-title>TH1/TH2 cytokine balance in patients with both type 1 diabetes mellitus and asthma</article-title><source>Cytokine</source><volume>34</volume><fpage>170</fpage><lpage>176</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.cyto.2006.04.012</pub-id><pub-id pub-id-type="pmid">16765604</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-3694"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikoopour</surname><given-names>E</given-names></name><name><surname>Schwartz</surname><given-names>JA</given-names></name><name><surname>Huszarik</surname><given-names>K</given-names></name><name><surname>Sandrock</surname><given-names>C</given-names></name><name><surname>Krougly</surname><given-names>O</given-names></name><name><surname>Lee-Chan</surname><given-names>E</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name></person-group><article-title>Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes</article-title><source>J Immunol</source><volume>184</volume><fpage>4779</fpage><lpage>4788</lpage><year>2010</year><pub-id pub-id-type="doi">10.4049/jimmunol.0902822</pub-id><pub-id pub-id-type="pmid">20363968</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-3694"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>T</given-names></name><name><surname>Krougly</surname><given-names>O</given-names></name><name><surname>Nikoopour</surname><given-names>E</given-names></name><name><surname>Bellemore</surname><given-names>S</given-names></name><name><surname>Lee-Chan</surname><given-names>E</given-names></name><name><surname>Fouser</surname><given-names>LA</given-names></name><name><surname>Hill</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name></person-group><article-title>The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes</article-title><source>Cell Regen (Lond)</source><volume>2</volume><month>Apr</month><day>4</day><year>2013</year><comment>(Epub ahead of print). doi: 10.1186/2045-9769-2-2</comment><pub-id pub-id-type="pmid">25408874</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-3694"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vong</surname><given-names>AM</given-names></name><name><surname>Daneshjou</surname><given-names>N</given-names></name><name><surname>Norori</surname><given-names>PY</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Braciak</surname><given-names>T</given-names></name><name><surname>Sercarz</surname><given-names>EE</given-names></name><name><surname>Gabaglia</surname><given-names>CR</given-names></name></person-group><article-title>Spectratyping analysis of the islet-reactive T cell repertoire in diabetic NOD Ig&#x00B5;(null) mice after polyclonal B cell reconstitution</article-title><source>J Transl Med</source><volume>9</volume><fpage>1</fpage><lpage>10</lpage><year>2011</year><pub-id pub-id-type="doi">10.1186/1479-5876-9-101</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-3694"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>N</given-names></name><name><surname>Pires</surname><given-names>AE</given-names></name><name><surname>Gabriel</surname><given-names>AM</given-names></name><name><surname>Goulart</surname><given-names>LF</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Leal</surname><given-names>B</given-names></name><name><surname>Queiros</surname><given-names>AC</given-names></name><name><surname>Chaara</surname><given-names>W</given-names></name><name><surname>Moraes-Fontes</surname><given-names>MF</given-names></name><name><surname>Vasconcelos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells</article-title><source>J Clin Immunol</source><volume>33</volume><fpage>349</fpage><lpage>360</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s10875-012-9816-7</pub-id><pub-id pub-id-type="pmid">23064977</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-3694"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablamunits</surname><given-names>V</given-names></name><name><surname>Henegariu</surname><given-names>O</given-names></name><name><surname>Hansen</surname><given-names>JB</given-names></name><name><surname>Opare-Addo</surname><given-names>L</given-names></name><name><surname>Preston-Hurlburt</surname><given-names>P</given-names></name><name><surname>Santamaria</surname><given-names>P</given-names></name><name><surname>Mandrup-Poulsen</surname><given-names>T</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name></person-group><article-title>Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: Evidence of improved immune regulation</article-title><source>Diabetes</source><volume>61</volume><fpage>145</fpage><lpage>154</lpage><year>2012</year><pub-id pub-id-type="doi">10.2337/db11-1033</pub-id><pub-id pub-id-type="pmid">22043003</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-3694"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shon</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group><article-title>Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin</article-title><source>Experimental Diabetes Research</source><year>2012</year><month>Sep</month><day>27</day><year>2012</year><comment>(Epub ahead of print). doi: 10.1155/2012/210821</comment><pub-id pub-id-type="doi">10.1155/2012/210821</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-3694"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachapati</surname><given-names>K</given-names></name><name><surname>Bednar</surname><given-names>KJ</given-names></name><name><surname>Adams</surname><given-names>DE</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Mittler</surname><given-names>RS</given-names></name><name><surname>Jordan</surname><given-names>MB</given-names></name><name><surname>Hinerman</surname><given-names>JM</given-names></name><name><surname>Herr</surname><given-names>AB</given-names></name><name><surname>Ridgway</surname><given-names>WM</given-names></name></person-group><article-title>Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice</article-title><source>J Autoimmun</source><volume>47</volume><fpage>94</fpage><lpage>103</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jaut.2013.09.002</pub-id><pub-id pub-id-type="pmid">24145149</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-3694"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryani</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Richmond</surname><given-names>J</given-names></name><name><surname>Lock</surname><given-names>RB</given-names></name></person-group><article-title>Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program</article-title><source>Cancer Res</source><volume>75</volume><fpage>3276</fpage><year>2015</year><pub-id pub-id-type="doi">10.1158/1538-7445.AM2015-3276</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-3694"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>E</given-names></name><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Walters</surname><given-names>S</given-names></name><name><surname>Liuwantara</surname><given-names>D</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Grey</surname><given-names>ST</given-names></name></person-group><article-title>CD4(&#x002B;)CD25(&#x002B;) T-cells control autoimmunity in the absence of B-cells</article-title><source>Diabetes</source><volume>58</volume><fpage>1568</fpage><lpage>1577</lpage><year>2009</year><pub-id pub-id-type="doi">10.2337/db08-1504</pub-id><pub-id pub-id-type="pmid">19336675</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-3694"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gan</surname><given-names>RY</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>DP</given-names></name><name><surname>Li</surname><given-names>HB</given-names></name></person-group><article-title>Impacts of gut bacteria on human health and diseases</article-title><source>Int J Mol Sci</source><volume>16</volume><fpage>7493</fpage><lpage>7519</lpage><year>2015</year><pub-id pub-id-type="doi">10.3390/ijms16047493</pub-id><pub-id pub-id-type="pmid">25849657</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-3694"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zechner</surname><given-names>D</given-names></name><name><surname>Spitzner</surname><given-names>M</given-names></name><name><surname>Bobrowski</surname><given-names>A</given-names></name><name><surname>Knapp</surname><given-names>N</given-names></name><name><surname>Kuhla</surname><given-names>A</given-names></name><name><surname>Vollmar</surname><given-names>B</given-names></name></person-group><article-title>Diabetes aggravates acute pancreatitis and inhibits pancreas regeneration in mice</article-title><source>Diabetologia</source><volume>55</volume><fpage>1526</fpage><lpage>1534</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00125-012-2479-3</pub-id><pub-id pub-id-type="pmid">22327285</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-3694"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attinkara</surname><given-names>R</given-names></name><name><surname>Mwinyi</surname><given-names>J</given-names></name><name><surname>Truninger</surname><given-names>K</given-names></name><name><surname>Regula</surname><given-names>J</given-names></name><name><surname>Gaj</surname><given-names>P</given-names></name><name><surname>Rogler</surname><given-names>G</given-names></name><name><surname>Kullak-Ublick</surname><given-names>GA</given-names></name><name><surname>Eloranta</surname><given-names>JJ</given-names></name></person-group><article-title>Swiss IBD Cohort Study Group: Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease</article-title><source>BMC Res Notes</source><volume>5</volume><fpage>1</fpage><lpage>12</lpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1756-0500-5-461</pub-id><pub-id pub-id-type="pmid">22214347</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-3694" position="float">
<label>Figure 1.</label>
<caption><p>IL-10 local expression in pancreatic tissues (hematoxylin and eosin, &#x00D7;400) of mice in low-dose group A.</p></caption>
<graphic xlink:href="etm-12-05-2893-g00.tif"/>
</fig>
<fig id="f2-etm-0-0-3694" position="float">
<label>Figure 2.</label>
<caption><p>IL-10 local expression in pancreatic tissues (hematoxylin and eosin, &#x00D7;400) of mice in medium-dose group B.</p></caption>
<graphic xlink:href="etm-12-05-2893-g01.tif"/>
</fig>
<fig id="f3-etm-0-0-3694" position="float">
<label>Figure 3.</label>
<caption><p>IL-10 local expression in pancreatic tissues (hematoxylin and eosin, &#x00D7;400) of mice in high-dose group C.</p></caption>
<graphic xlink:href="etm-12-05-2893-g02.tif"/>
</fig>
<fig id="f4-etm-0-0-3694" position="float">
<label>Figure 4.</label>
<caption><p>IL-10 local expression in pancreatic tissues (hematoxylin and eosin, &#x00D7;400) of mice in control group D.</p></caption>
<graphic xlink:href="etm-12-05-2893-g03.tif"/>
</fig>
<fig id="f5-etm-0-0-3694" position="float">
<label>Figure 5.</label>
<caption><p>Variation of mouse pancreatic CD4&#x002B;CD25&#x002B;T-cell subset proportion in low-dose group A.</p></caption>
<graphic xlink:href="etm-12-05-2893-g04.tif"/>
</fig>
<fig id="f6-etm-0-0-3694" position="float">
<label>Figure 6.</label>
<caption><p>Variation of mouse pancreatic CD4&#x002B;CD25&#x002B;T-cell subset proportion in medium-dose group B.</p></caption>
<graphic xlink:href="etm-12-05-2893-g05.tif"/>
</fig>
<fig id="f7-etm-0-0-3694" position="float">
<label>Figure 7.</label>
<caption><p>Variation of mouse pancreatic CD4&#x002B;CD25&#x002B;T-cell subset proportion in high-dose group C.</p></caption>
<graphic xlink:href="etm-12-05-2893-g06.tif"/>
</fig>
<fig id="f8-etm-0-0-3694" position="float">
<label>Figure 8.</label>
<caption><p>Variation of mouse pancreatic CD4&#x002B;CD25&#x002B;T-cell subset proportion in control group D.</p></caption>
<graphic xlink:href="etm-12-05-2893-g07.tif"/>
</fig>
<table-wrap id="tI-etm-0-0-3694" position="float">
<label>Table I.</label>
<caption><p>Comparison of serum IL-2, IL-10 and IFN-&#x03B3; in the four groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Group</th>
<th align="center" valign="bottom">No.</th>
<th align="center" valign="bottom">IL-2 (pg/ml)</th>
<th align="center" valign="bottom">IL-10 (pg/ml)</th>
<th align="center" valign="bottom">IFN-&#x03B3; (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Low-dose group A</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">61.12&#x00B1;9.48<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="top">195.67&#x00B1;20.15<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="top">321.36&#x00B1;28.26<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">Medium-dose group B</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">58.36&#x00B1;8.97<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>,<xref rid="tfn3-etm-0-0-3694" ref-type="table-fn">b</xref></sup></td>
<td align="center" valign="top">213.92&#x00B1;21.84<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>,<xref rid="tfn3-etm-0-0-3694" ref-type="table-fn">b</xref></sup></td>
<td align="center" valign="top">303.46&#x00B1;25.37<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>,<xref rid="tfn3-etm-0-0-3694" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">High-dose group C</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">53.15&#x00B1;8.26<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>&#x2013;<xref rid="tfn4-etm-0-0-3694" ref-type="table-fn">c</xref></sup></td>
<td align="center" valign="top">238.72&#x00B1;23.34<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>&#x2013;<xref rid="tfn4-etm-0-0-3694" ref-type="table-fn">c</xref></sup></td>
<td align="center" valign="top">285.48&#x00B1;22.65<sup><xref rid="tfn2-etm-0-0-3694" ref-type="table-fn">a</xref>&#x2013;<xref rid="tfn4-etm-0-0-3694" ref-type="table-fn">c</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">Control group D</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">81.34&#x00B1;10.27</td>
<td align="center" valign="top">162.66&#x00B1;18.37</td>
<td align="center" valign="top">363.57&#x00B1;31.28</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-etm-0-0-3694"><p>Compared with control group D</p></fn>
<fn id="tfn2-etm-0-0-3694"><label>a</label><p>P&#x003C;0.05; compared with low-dose group A</p></fn>
<fn id="tfn3-etm-0-0-3694"><label>b</label><p>P&#x003C;0.05; compared with medium-dose group B</p></fn>
<fn id="tfn4-etm-0-0-3694"><label>c</label><p>P&#x003C;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
